Skip to main content

Advertisement

SpringerLink
Log in

Excellent long-term survival of 170 patients with Waldenström’s macroglobulinemia treated in private oncology practices and a university hospital

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

The purpose of this study was to compare treatment and outcome of patients with Waldenström’s macroglobulinemia (WM) in four private oncology practices (PP) and a university hospital (UH) in southwest Germany. We retrospectively reviewed the charts of all patients with WM of the last two decades of four PP in Mannheim, Heidelberg, Karlsruhe, and Speyer and the Department of Hematology of the University of Heidelberg. One hundred seventy patients could be identified, 74 from PP, 96 from the UH. Median age was 63.3 years. Patients from PP were older (median 65.3 vs. 62.5 years, p = 0.01). Only 54 % of patients from PP have received treatment during the observation time, as compared to 78.1 % of the UH (p < 0.001). In PP, 35 % of treated patients have received rituximab, as compared to 62.6 % of the patients of the UH (p < 0.001). Sixty percent of treated patients of PP have received bendamustine, as compared to only 8 % of the patients of the UH (p < 0.001). Time to first treatment was significantly shorter in patients from the UH compared to PP (median 13.7 vs. 52.9 months, p = 0.05). A trend towards a better overall survival was observed for patients treated with a rituximab-containing first-line regimen. The International Prognostic Scoring System for WM had significant prognostic value. Median overall survival was 25.0 years and did not differ between PP and UH. Despite different treatment strategies between PP and UH today overall survival of patients with WM is excellent, and better than previously reported.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Baehring JM, Hochberg EP et al (2008) Neurological manifestations of Waldenstrom macroglobulinemia. Nat Clin Pract Neurol 4(10):547–556

    Article  PubMed  CAS  Google Scholar 

  2. Berentsen S (2009) Cold agglutinin-mediated autoimmune hemolytic anemia in Waldenstrom’s macroglobulinemia. Clin Lymphoma Myeloma 9(1):110–112

    Article  PubMed  Google Scholar 

  3. Buske C, Hoster E et al (2009) The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia 23(1):153–161

    Article  PubMed  CAS  Google Scholar 

  4. Dimopoulos MA, Anagnostopoulos A et al (2007) Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 25(22):3344–3349

    Article  PubMed  CAS  Google Scholar 

  5. Gertz MA (2010) Current status of stem cell mobilization. Br J Haematol 150(6):647–662

    Article  PubMed  CAS  Google Scholar 

  6. Gertz MA, Kyle RA et al (1993) Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenstrom’s macroglobulinemia. J Clin Oncol 11(5):914–920

    PubMed  CAS  Google Scholar 

  7. Gertz MA, Rue M et al (2004) Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma 45(10):2047–2055

    Article  PubMed  CAS  Google Scholar 

  8. Gertz MA, Reeder CB et al. (2011) Stem cell transplant for Waldenstrom macroglobulinemia: an underutilized technique. Bone Marrow Transplant. doi:10.1038/bmt.2011.175

  9. Ghobrial IM, Uslan DZ et al (2004) Initial increase in the cryoglobulin level after rituximab therapy for type II cryoglobulinemia secondary to Waldenstrom macroglobulinemia does not indicate failure of response. Am J Hematol 77(4):329–330

    Article  PubMed  Google Scholar 

  10. Ghobrial IM, Gertz M et al (2010) Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol 28(8):1408–1414

    Article  PubMed  CAS  Google Scholar 

  11. Ghobrial IM, Hong F et al (2010) Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol 28(8):1422–1428

    Article  PubMed  CAS  Google Scholar 

  12. Grant S (2011) Targeting Waldenstrom macroglobulinemia with histone deacetylase inhibitors. Leuk Lymphoma 52(9):1623–1625

    Article  PubMed  CAS  Google Scholar 

  13. Hensel M, Villalobos M et al (2005) Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom’s macroglobulinemia/lymphoplasmacytic lymphoma. Clin Lymphoma Myeloma 6(2):131–135

    Article  PubMed  Google Scholar 

  14. Hivert B, Tamburini J et al (2011) Prognostic value of the International Scoring System and response in patients with advanced Waldenstrom macroglobulinemia. Haematologica 96(5):785–788

    Article  PubMed  Google Scholar 

  15. Hutchins LF, Unger JM et al (1999) Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341(27):2061–2067

    Article  PubMed  CAS  Google Scholar 

  16. Ioakimidis L, Patterson CJ et al (2009) Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenstrom’s macroglobulinemia. Clin Lymphoma Myeloma 9(1):62–66

    Article  PubMed  CAS  Google Scholar 

  17. Issa GC, Ghobrial IM et al (2011) Novel agents in Waldenstrom macroglobulinemia. Clin Investig (Lond) 1(6):815–824

    Article  CAS  Google Scholar 

  18. Kyle RA, Garton JP (1987) The spectrum of IgM monoclonal gammopathy in 430 cases. Mayo Clin Proc 62(8):719–731

    PubMed  CAS  Google Scholar 

  19. Kyle RA, Treon SP et al (2003) Prognostic markers and criteria to initiate therapy in Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol 30(2):116–120

    Article  PubMed  Google Scholar 

  20. Loberiza FR Jr, Cannon AJ et al (2009) Survival disparities in patients with lymphoma according to place of residence and treatment provider: a population-based study. J Clin Oncol 27(32):5376–5382

    Article  PubMed  Google Scholar 

  21. Morel P, Duhamel A et al (2009) International prognostic scoring system for Waldenstrom macroglobulinemia. Blood 113(18):4163–4170

    Article  PubMed  CAS  Google Scholar 

  22. Owen RG, Treon SP et al (2003) Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol 30(2):110–115

    Article  PubMed  Google Scholar 

  23. Peinert S, Tam CS et al (2010) Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenstrom macroglobulinemia. Leuk Lymphoma 51(12):2188–2197

    Article  PubMed  CAS  Google Scholar 

  24. Pisters PW, Blanke CD et al (2011) A USA registry of gastrointestinal stromal tumor patients: changes in practice over time and differences between community and academic practices. Ann Oncol 22(11):2523–2529

    Article  PubMed  CAS  Google Scholar 

  25. Roccaro AM, Sacco A et al (2010) Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood 115(3):559–569

    Article  PubMed  CAS  Google Scholar 

  26. Rummel M (2009) Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to chop plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III Study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 114(22), ASH Annual Meeting Abstract 405

  27. Stone MJ (2009) Waldenstrom’s macroglobulinemia: hyperviscosity syndrome and cryoglobulinemia. Clin Lymphoma Myeloma 9(1):97–99

    Article  PubMed  Google Scholar 

  28. Tedeschi A, Alamos SM et al (2009) Fludarabine-based combination therapies for Waldenstrom’s macroglobulinemia. Clin Lymphoma Myeloma 9(1):67–70

    Article  PubMed  CAS  Google Scholar 

  29. van Oost FJ, Luiten EJ et al (2006) Outcome of surgical treatment of pancreatic, peri-ampullary and ampullary cancer diagnosed in the south of The Netherlands: a cancer registry based study. Eur J Surg Oncol 32(5):548–552

    Article  PubMed  Google Scholar 

  30. Wong SJ, Harari PM et al (2011) Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN): analysis of chemoradiation treatment approaches in the United States. Cancer 117(8):1679–1686

    Article  PubMed  Google Scholar 

Download references

Disclaimers

None.

Author information

Authors and Affiliations

  1. Mannheimer Onkologie Praxis, Mannheim, Germany

    M. Hensel, J. Brust, C. Plöger & D. Schuster

  2. Department of Internal Medicine V (Hematology and Oncology), University of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany

    M. L. Memmer, M. Rieger, A. D. Ho & M. Witzens-Harig

  3. Onkologische Schwerpunktpraxis Karlsruhe, Karlsruhe, Germany

    F. A. Mosthaf

  4. Onkologische Schwerpunktpraxis Speyer, Speyer, Germany

    J. Franz-Werner & H.-P. Feustel

  5. Onkologische Schwerpunktpraxis Heidelberg, Heidelberg, Germany

    A. Karcher & S. Fuxius

Authors
  1. M. Hensel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Brust
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Plöger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. Schuster
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. L. Memmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. Franz-Werner
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H.-P. Feustel
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Karcher
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S. Fuxius
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. F. A. Mosthaf
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M. Rieger
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. A. D. Ho
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. M. Witzens-Harig
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Witzens-Harig.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hensel, M., Brust, J., Plöger, C. et al. Excellent long-term survival of 170 patients with Waldenström’s macroglobulinemia treated in private oncology practices and a university hospital. Ann Hematol 91, 1923–1928 (2012). https://doi.org/10.1007/s00277-012-1545-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-012-1545-8

Keywords

Search

Navigation